2 Neurofeedback Protocols in the Treatment of Attention Deficit Hyperactivity Disorder in Children and Adolescents

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-21

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Attention Deficit Disorder with or without Hyperactivity (ADD / H) is a public health problem since it has short and long-term consequences, affects about 5% of children of school age but remains unknown and therefore under- diagnostic.

The investigator will performed a controlled and randomized research to compare the effects of two neurofeedback protocols on the repercussions of Attention Deficit AD / Hyperactivity Disorder (HD) symptoms, in particular the hyperactivity on which the improvements reported in the literature are less with usual protocols.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NEUROFEEDBACK on Event-Related Potential (ERP)

NCT03289793

Attention Deficit Disorder With Hyperactivity

COMPLETED NA

Effects of a Novel Neurofeedback Protocol on ADHD Subcomponents

NCT04408521

Attention Deficit Disorder With Hyperactivity

ACTIVE_NOT_RECRUITING NA

Near-infrared Spectroscopy Neurofeedback as a Treatment for Children With Attention Deficit Hyperactivity Disorder

NCT04065906

Neurofeedback Attention Deficit Hyperactivity Disorder (ADHD)

UNKNOWN NA

Efficacy of Neurofeedback Training in Adults With ADHD

NCT01883765

Attention Deficit Hyperactivity Disorder

COMPLETED NA

NIRS Neurofeedback as a Treatment for Attention Deficit Hyperactivity Disorder

NCT02333422

Attention Deficit Hyperactivity Disorder

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Attention deficit disorder with or without hyperactivity (ADD / H) is a public health problem since it has short and long-term consequences, affects about 5% of children of school age but remains unknown and therefore under- diagnostic. In the symptomatic triad of inattention, impulsivity and hyperactivity, there is often a psychopathological disorder, a learning and / or sleep disorder. Medication treatment with methylphenidate is the reference in terms of prescription to reduce the symptoms of AD / HD. However, the limitations of its long-term effectiveness, tolerance of side effects, and parental distrust of psychostimulant treatment are gradually opening the door to new therapeutic approaches.

Neurofeedback is considered by the scientific world as a promising and effective neurocognitive learning technique in the treatment of Attention Deficit Disorder with Hyperactivity ADHD and several neurological and psychiatric disorders. Its principle is to increase the patient's ability to regulate his own brain activity, captured by an ElectroEncephaloGram (EEG), after visual and auditory feedback.

In this controlled and randomized research, the investigator will compare the effects of two neurofeedback protocols on the repercussions of AD / HD symptoms, in particular the hyperactivity on which the improvements reported in the literature are less with usual protocols.

Seventy children and adolescents aged 7 to 15 in two groups will benefit from thirty neurofeedback sessions each, either on a so-called Sensory Motor Rhythm (SMR) protocol or on a protocol called Upper Alpha. To date, no studies have identified the effects of a NF Upper Alpha protocol on improving sleep, hyperactivity and comorbidities in patients with ADHD in a controlled and randomized manner. nor on personality dimensions related to the processes of self-regulation of the patient involved in Neurofeedback (NF) treatment.

The investigator expects superior clinical improvement of ADHD symptoms and sleep disorders in the NF upper alpha training group in patients not following any parallel drug or therapy regimen. The investigator expects stability of the effects of treatment after several months of stopping neurofeedback sessions, without taking or recovery of psychostimulant.

This research protocol would make it possible for dozens of children and adolescents to benefit from an alternative treatment (in the absence of placebo conditions) in order to achieve a clinical improvement of at least 30% of their patients. symptoms related to AD / HD, as well as to develop a field of research still little investigated in France. On the other hand, parents would be more likely to accept effective neurofeedback treatment than psychostimulant treatment, especially since it may have side effects. In addition, the validation of clinical improvements following a neurofeedback protocol aimed at increasing the relative power of alpha waves at frontal sites would be encouraging for clinical practice and future research in this area.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ADHD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

single-center interventional biomedical research with direct individual benefit, randomized with two active arms (without placebo)

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SMR Sensory Motor Rhythm (12-15 Hz)

3 X 10 SMR workout sessions (12-15 Hz) C4 unipolar placement, central region

Group Type EXPERIMENTAL

SMR (12-15 Hz)

Intervention Type OTHER

SMR training sessions (12-15 Hz) C4 unipolar placement, central region

the alpha band (8 -12Hz)

3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region

Group Type EXPERIMENTAL

alpha band (8 -12Hz)

Intervention Type OTHER

3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SMR (12-15 Hz)

SMR training sessions (12-15 Hz) C4 unipolar placement, central region

Intervention Type OTHER

alpha band (8 -12Hz)

3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children or teenagers between 8 and 15 years old included
* Subject with mixed-type ADHD (attention deficit hyperactivity disorder) diagnosed by a specialist physician in the field and according to Diagnosis and Statistics of Mental Disorders-5 (DSM-5) criteria.
* Subject of any psychotropic treatment for at least 15 days before inclusion
* Subject committing not to take any treatment during the study period, nor to participate in another therapeutic treatment in parallel.
* Subject available and pledging to honor the two weekly neurofeedback sessions for 15 consecutive weeks, and be available for symptom monitoring at 6 months.
* Child benefiting from a Social Security scheme.

* Neurological disorders (epilepsy)
* Trouble of the autistic spectrum
* Active disorder without hyperactivity (TDA)
* Bad understanding of the French language
* Low Intellectual Level (IQ \<70 Cognitive Assessment)
* Lack of understanding of the constraints inherent in the protocol
* Inability to comply with the constraints of the study throughout its duration

Exclusion Criteria

* premature termination of participation, withdrawal of the patient's voluntary informed consent
* Investigator's or sponsor's decision
* Withdrawal of consent of subjects or legal guardians

Minimum Eligible Age

8 Years

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No